JP2023505301A - 急性骨髄性白血病または骨髄異形成症候群に対する治療 - Google Patents

急性骨髄性白血病または骨髄異形成症候群に対する治療 Download PDF

Info

Publication number
JP2023505301A
JP2023505301A JP2022534233A JP2022534233A JP2023505301A JP 2023505301 A JP2023505301 A JP 2023505301A JP 2022534233 A JP2022534233 A JP 2022534233A JP 2022534233 A JP2022534233 A JP 2022534233A JP 2023505301 A JP2023505301 A JP 2023505301A
Authority
JP
Japan
Prior art keywords
compound
lymphoma
leukemia
cell
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505301A5 (enExample
Inventor
アール． ブレイ，マーク
エム． メーソン，ジャクリーン
フレッチャー，グラハム
Original Assignee
ユニバーシティー ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー ヘルス ネットワーク filed Critical ユニバーシティー ヘルス ネットワーク
Publication of JP2023505301A publication Critical patent/JP2023505301A/ja
Publication of JP2023505301A5 publication Critical patent/JP2023505301A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022534233A 2019-12-06 2020-12-04 急性骨髄性白血病または骨髄異形成症候群に対する治療 Pending JP2023505301A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944876P 2019-12-06 2019-12-06
US62/944,876 2019-12-06
PCT/CA2020/051668 WO2021108918A1 (en) 2019-12-06 2020-12-04 Treatment for acute myeloid leukemia or myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
JP2023505301A true JP2023505301A (ja) 2023-02-08
JP2023505301A5 JP2023505301A5 (enExample) 2023-12-11

Family

ID=76221282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534233A Pending JP2023505301A (ja) 2019-12-06 2020-12-04 急性骨髄性白血病または骨髄異形成症候群に対する治療

Country Status (12)

Country Link
US (1) US12533357B2 (enExample)
EP (1) EP4069246A4 (enExample)
JP (1) JP2023505301A (enExample)
KR (1) KR20220124177A (enExample)
CN (1) CN115397429A (enExample)
AU (1) AU2020396807B2 (enExample)
BR (1) BR112022011052A2 (enExample)
CA (1) CA3163796A1 (enExample)
IL (1) IL293623A (enExample)
MX (1) MX2022006910A (enExample)
TW (1) TWI880995B (enExample)
WO (1) WO2021108918A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
TWI926033B (zh) 2021-05-11 2026-05-21 美商歐瑞克製藥公司 類ｐｏｌｏ激酶４抑制劑
TW202333712A (zh) * 2021-12-22 2023-09-01 加拿大健康網路大學 於急性骨髓性白血病或淋巴瘤之治療
CN117180295A (zh) * 2023-09-13 2023-12-08 华东医院 一种用于治疗tp53突变髓系肿瘤的药物组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115279A1 (en) 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
CA2803446C (en) * 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
EP3052102B1 (en) 2013-10-04 2019-12-04 Aptose Biosciences Inc. Compositions for treating cancers
TR201902875T4 (tr) * 2013-10-18 2019-03-21 Univ Health Network Plk-4 inhibitörünün tuz ve kristal formları.
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
KR20190129889A (ko) 2017-03-31 2019-11-20 노파르티스 아게 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법
US11612604B2 (en) * 2017-12-06 2023-03-28 Ludwig Institute For Cancer Research Ltd Methods of treating cancer with PLK4 inhibitors
EP3959209A4 (en) 2019-04-24 2022-12-28 University Health Network S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. Vol.134 Iss.Suppl_1, JPN6024043753, November 2019 (2019-11-01), ISSN: 0005565434 *
BLOOD, vol. Vol.136 Iss.Suppl_1, JPN6024043750, November 2020 (2020-11-01), ISSN: 0005565433 *
CANCER CELL, vol. 26, JPN6024043751, 2014, pages 163 - 176, ISSN: 0005565436 *
RECORD HISTORY OF NCT03187288, JPN6024043752, 2018, ISSN: 0005565435 *

Also Published As

Publication number Publication date
AU2020396807A1 (en) 2022-07-21
US12533357B2 (en) 2026-01-27
EP4069246A1 (en) 2022-10-12
MX2022006910A (es) 2022-11-09
US20230010772A1 (en) 2023-01-12
CA3163796A1 (en) 2021-06-10
IL293623A (en) 2022-08-01
CN115397429A (zh) 2022-11-25
BR112022011052A2 (pt) 2022-08-16
EP4069246A4 (en) 2023-12-06
WO2021108918A1 (en) 2021-06-10
TW202134237A (zh) 2021-09-16
AU2020396807B2 (en) 2026-07-16
TWI880995B (zh) 2025-04-21
KR20220124177A (ko) 2022-09-13

Similar Documents

Publication Publication Date Title
TWI880995B (zh) 急性骨髓性白血病或骨髓發育不良症候群的治療
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
EP3013335A1 (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
EP3703755B1 (en) Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors for use in the treatment of cancer
US20200289520A1 (en) Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
US20210401851A1 (en) Par-4 agonists for the treatment of cancer
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
JP7242097B2 (ja) 免疫チェックポイント抑制剤を含む抗がん用組成物
TWI849001B (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
CN113509475A (zh) Bcl-2/bcl-xl抑制剂的组合及相关用途
US20230132982A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
EA049792B1 (ru) Лечение острого миелоидного лейкоза или миелодиспластического синдрома
JP7822619B2 (ja) 胆管癌の処置のためのパノビノスタットを含む併用療法
IL300145A (en) A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations
WO2026057039A1 (zh) 含吡咯并吡啶的化合物在治疗肿瘤中的应用
DK2994126T3 (en) Combination of a PI3 kinase inhibitor with paclitaxel for use in the treatment or prevention of head and neck cancer
CN121285550A (zh) 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途
CN117042771A (zh) 使用serd给药方案的组合治疗癌症的方法
HK1129853B (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241030

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250402